Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects

Frasier, 2010, The Parkinson's progression markers initiative: a prospective biomarker study, Movement Disorders, 25, P340 Hall, 2012, Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or Parkinsonian disorders, Archives of Neurology, 1, 10.1001/archneurol.2012.1654 Hong, 2010, DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease, Brain, 133, 713, 10.1093/brain/awq008 Kasuga, 2010, Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease, Journal of Neurology, Neurosurgery and Psychiatry, 81, 608, 10.1136/jnnp.2009.197483 Mignini, 2000, Dopamine receptor immunohistochemistry in the rat choroid plexus, Journal of Autonomic Pharmacology, 20, 325, 10.1046/j.1365-2680.2000.00198.x Mollenhauer, 2008, Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration, Experimental Neurology, 213, 315, 10.1016/j.expneurol.2008.06.004 Mollenhauer, 2010, Quantification of alpha-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies, Biomarkers Medicine, 4, 683, 10.2217/bmm.10.90 Mollenhauer, 2011, alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with Parkinsonism: a cohort study, Lancet Neurology, 10, 230, 10.1016/S1474-4422(11)70014-X Mollenhauer, 2008, Purification and quantification of neural alpha-synuclein: relevance for pathogenesis and biomarker development, 559 Mollenhauer, 2012, alpha-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system, Journal of Neural Transmission, 119, 739, 10.1007/s00702-012-0784-0 Noguchi-Shinohara, 2009, CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease, Brain Research, 1251, 1, 10.1016/j.brainres.2008.11.055 Ohrfelt, 2009, Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?, Neuroscience Letters, 450, 332, 10.1016/j.neulet.2008.11.015 Mollenhauer, 2011, CSF α-synuclein, tau, and amyloid-β in Parkinson's disease, Lancet Neurology, 10, 681, 10.1016/S1474-4422(11)70161-2 Spies, 2009, Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders, Journal of Alzheimer's Disease, 16, 363, 10.3233/JAD-2009-0955 Tateno, 2012, Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease, Alzheimer Disease and Associated Disorders, 26, 213, 10.1097/WAD.0b013e31823899cc Tokuda, 2010, Detection of elevated levels of {alpha}-synuclein oligomers in CSF from patients with Parkinson disease, Neurology, 75, 1766, 10.1212/WNL.0b013e3181fd613b Tokuda, 2006, Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease, Biochemical and Biophysical Research Communications, 349, 162, 10.1016/j.bbrc.2006.08.024 Wang, 2012, Phosphorylated alpha-synuclein in Parkinson's disease, Science Translational Medicine, 4, 121ra20, 10.1126/scitranslmed.3002566 Wennstrom, 2012, Altered CSF orexin and alpha-synuclein levels in dementia patients, Journal of Alzheimer's Disease, 29, 125, 10.3233/JAD-2012-111655